Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Chinese Robotaxi Stocks Rally as Tesla Boosts Autonomous Driving Optimism 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Asian Markets Rebound as Tech Rally Lifts Wall Street, Investors Brace for BOJ Rate Hike 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Canada Signals Delay in US Tariff Deal as Talks Shift to USMCA Review 
Trump Defends Economic Record in North Carolina as Midterm Election Pressure Mounts 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Dollar Holds Firm Ahead of Global Central Bank Decisions as Yen, Sterling and Euro React 
Kevin Hassett Says Inflation Is Below Target, Backs Trump’s Call for Rate Cuts 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Illumina Inc., the DNA-sequencing giant, announced the resignation of CEO Francis deSouza and the interim appointment of Charles Dadswell, previously the firm's SVP and General Counsel. The unexpected departure is seen as a victory for activist investor Carl Icahn, who had been pushing for deSouza's removal.
Prior to his appointment, Dadswell served as the senior vice president and general counsel at Illumina Inc. DeSouza's resignation was seen as a victory for activist investor Carl Icahn as he has been trying to remove the CEO from the DNA-sequencing firm.
As per Fortune, the outgoing chief survived Icahn's attacks on him after he was re-elected to the company's board late last month. He was among the eight executives to have earned a spot on the board, and the American financier was apparently against it.
The 87-year-old activist investor was said to have started pushing for board seats as early as March and criticized Illumina's board and management for selling and then buying back Grail Inc. later at a higher price. He also lambastes the company for pushing through with the deal even if the regulators in Europe opposed it.
Now, weeks after Icahn's failure to oust DeSouza, Illumina confirmed on Sunday, June 11, that its board of directors received the CEO's resignation, and they have accepted it. The company also released a statement for his departure and revealed its transition plans as well.
"We thank Francis for his contributions and leadership, and are very excited about embarking on the next chapter of Illumina's great journey," Illumina's chairman of the board, Stephen P. MacMillan, said in a press release. "Illumina's technology remains at the forefront of DNA sequencing and has continued to set the pace for the industry. We are confident Illumina can continue to execute on its goals while we conduct and complete a CEO search process."
Finally, Illumina said that as part of its transition plans, it is now looking for an executive who will permanently take over the role of CEO. The search will include both internal and external candidates. While DeSouza's resignation is already in effect, he will stay in the company as an adviser until July 31.
Photo by: Illumina/Wikimedia Commons(Public Domain)
_logo.jpg){kind=link}